Literature DB >> 33886059

A review of possible therapies for multiple sclerosis.

Hui Li1, Gaojian Lian1, Guang Wang1, Qianmei Yin1, Zehong Su2.   

Abstract

Multiple sclerosis (MS) is an autoimmune chronic inflammatory disease of the central nervous system with a wide range of symptoms, like executive function defect, cognitive dysfunction, blurred vision, decreased sensation, spasticity, fatigue, and other symptoms. This neurological disease is characterized by the destruction of the blood-brain barrier, loss of myelin, and damage to neurons. It is the result of immune cells crossing the blood-brain barrier into the central nervous system and attacking self-antigens. Heretofore, many treatments proved that they can retard the progression of the disease even though there is no cure. Therefore, treatments aimed at improving patients' quality of life and reducing adverse drug reactions and costs are essential. In this review, the treatment approaches to alleviate the progress of MS include the following: pharmacotherapy, antibody therapy, cell therapy, gene therapy, and surgery. The current treatment methods of MS are described in terms of the prevention of myelin shedding, the promotion of myelin regeneration, and the protection of neurons.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cell therapy; Disease-modifying treatment; Gene therapy; Multiple sclerosis; Symptomatic therapy

Year:  2021        PMID: 33886059     DOI: 10.1007/s11010-021-04119-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  99 in total

Review 1.  Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis.

Authors:  Maria A Rocca; Maria P Amato; Nicola De Stefano; Christian Enzinger; Jeroen J Geurts; Iris-K Penner; Alex Rovira; James F Sumowski; Paola Valsasina; Massimo Filippi
Journal:  Lancet Neurol       Date:  2015-02-04       Impact factor: 44.182

2.  Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.

Authors:  Scott D Newsome; Oksana Mokliatchouk; Carmen Castrillo-Viguera; Maria L Naylor
Journal:  Mult Scler Relat Disord       Date:  2020-01-17       Impact factor: 4.339

Review 3.  Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.

Authors:  Anthony Feinstein; Jenny Freeman; Albert C Lo
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

Review 4.  Advances in the immunopathogenesis of multiple sclerosis.

Authors:  Sudhir K Yadav; John E Mindur; Kouichi Ito; Suhayl Dhib-Jalbut
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

5.  Pervasive axonal transport deficits in multiple sclerosis models.

Authors:  Catherine Diamante Sorbara; Naomi Elizabeth Wagner; Anne Ladwig; Ivana Nikić; Doron Merkler; Tatjana Kleele; Petar Marinković; Ronald Naumann; Leanne Godinho; Florence Martine Bareyre; Derron Bishop; Thomas Misgeld; Martin Kerschensteiner
Journal:  Neuron       Date:  2014-11-26       Impact factor: 17.173

Review 6.  Immunopathogenesis of multiple sclerosis.

Authors:  Manuel Comabella; Samia J Khoury
Journal:  Clin Immunol       Date:  2011-03-12       Impact factor: 3.969

Review 7.  Role of the innate and adaptive immune responses in the course of multiple sclerosis.

Authors:  Bernhard Hemmer; Martin Kerschensteiner; Thomas Korn
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

Review 8.  Multiple sclerosis: a complicated picture of autoimmunity.

Authors:  Henry F McFarland; Roland Martin
Journal:  Nat Immunol       Date:  2007-09       Impact factor: 25.606

9.  Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.

Authors:  Mauricio F Farez; Francisco J Quintana; Roopali Gandhi; Guillermo Izquierdo; Miguel Lucas; Howard L Weiner
Journal:  Nat Immunol       Date:  2009-08-16       Impact factor: 25.606

Review 10.  Multiple Sclerosis: New Aspects of Immunopathogenesis.

Authors:  Ines Lazibat; Maja Rubinić Majdak; Sven Županić
Journal:  Acta Clin Croat       Date:  2018-06       Impact factor: 0.780

View more
  1 in total

Review 1.  Excessive intake of sugar: An accomplice of inflammation.

Authors:  Xiao Ma; Fang Nan; Hantian Liang; Panyin Shu; Xinzou Fan; Xiaoshuang Song; Yanfeng Hou; Dunfang Zhang
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.